Guardant Health, Inc. (NASDAQ:GH – Get Free Report) shares reached a new 52-week high on Monday . The stock traded as high as $152.19 and last traded at $149.6370, with a volume of 4450 shares changing hands. The stock had previously closed at $149.22.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on GH shares. UBS Group set a $150.00 target price on shares of Guardant Health in a report on Wednesday, June 24th. Mizuho boosted their target price on shares of Guardant Health from $135.00 to $175.00 and gave the company an “outperform” rating in a research note on Monday, June 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. Sanford C. Bernstein started coverage on Guardant Health in a research note on Friday. They issued an “outperform” rating and a $175.00 price target on the stock. Finally, Evercore raised Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 price objective for the company in a report on Tuesday, June 2nd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Guardant Health currently has a consensus rating of “Buy” and an average price target of $144.82.
Check Out Our Latest Report on Guardant Health
Guardant Health Price Performance
Insider Activity
In related news, Director Meghan V. Joyce sold 10,000 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total value of $1,269,800.00. Following the completion of the sale, the director directly owned 11,183 shares of the company’s stock, valued at approximately $1,420,017.34. This represents a 47.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Amirali Talasaz sold 210,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $109.89, for a total transaction of $23,076,900.00. Following the sale, the chief executive officer owned 1,886,504 shares in the company, valued at approximately $207,307,924.56. The trade was a 10.02% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 452,513 shares of company stock worth $51,608,916. 5.60% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Guardant Health
Hedge funds have recently modified their holdings of the company. V Square Quantitative Management LLC bought a new stake in shares of Guardant Health during the 4th quarter valued at $27,000. Chesapeake Asset Management LLC bought a new position in Guardant Health in the 4th quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Guardant Health in the 4th quarter worth $31,000. Elyxium Wealth LLC purchased a new stake in Guardant Health in the 4th quarter worth $35,000. Finally, Parallel Advisors LLC increased its stake in Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after buying an additional 219 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.
Guardant Health Company Profile
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Featured Articles
- Five stocks we like better than Guardant Health
- Qualcomm’s Investor Day Just Changed the Growth Story Forever
- JPMorgan Stands by Sky-High Broadcom Target as Shares Slide
- 5 Places Investors Can Hide If the AI Trade Keeps Cracking
- Is Apple’s Latest Plunge the Canary in the Coal Mine for Tech Stocks?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
